OncoMatch/Clinical Trials/NCT06094101
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
Is NCT06094101 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Peptide vaccine IPX for ewing sarcoma.
Treatment: Peptide vaccine IPX — The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor. This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities. It is an interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study evaluating a personalized peptide vaccine. Primary objective is to evaluate safety and success of treatment, the latter be defined as vaccination-induced T-cell response without unacceptable toxicity.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Rhabdomyosarcoma
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: cytotoxic chemotherapy — intensive standard chemotherapy protocols
intensive standard chemotherapy protocols
Must have received: local therapy — all remaining tumor residua including all metastases have received local therapy (surgical removal or local irradiation)
all remaining tumor residua including all metastases have received local therapy by this time point: Either surgical removal or local irradiation
Must have received: adjuvant and/or maintenance cytotoxic treatment — completed
adjuvant and/or maintenance cytotoxic treatment ... has been completed
Cannot have received: haematopoietic stem cell transplantation
Subjects with a prior haematopoietic stem cell transplantation
Cannot have received: organ transplantation
prior organ transplantation
Lab requirements
Kidney function
Creatinine-clearance < 40ml/min
Liver function
Bilirubin > 4mg/dl; ALT > 400 U/l and/or AST > 400 U/l
Cardiac function
Ejection fraction < 25%
Ejection fraction < 25%; Creatinine-clearance < 40ml/min; Bilirubin > 4mg/dl; ALT > 400 U/l and/or AST > 400 U/l
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06094101 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior haematopoietic stem cell transplantation, organ transplantation disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 40 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages